
Opinion|Videos|July 22, 2024
The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
- How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
- What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
- How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
Advertisement
Related to this article

Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
4
Nondrug Therapies Ease Cough in Lung Cancer, Pulmonary Rehab Leads Pack
5


